American CryoStem Corporation Retains Investor Relations Partners as Investor Relations Counsel
Eatontown, NJ, April 1, 2016 – American CryoStem Corporation (Ticker: CRYO), a leading strategic developer, marketer and global licensor of patented adipose tissue-based cellular technologies for the Regenerative and Personalized Medicine industries, today announced that it has retained Investor Relations Partners (IRP) to expand the Company’s strategic investor relations program.
“We believe with the support and guidance of Investor Relations Partners we will be able to effectively communicate our story to the investment community,” said John S. Arnone, Chairman and Chief Executive Officer of American CryoStem Corporation. “We have a number of exciting developments at American CryoStem driven by our proprietary adipose tissue-based cellular technologies. We expect 2016 to be a breakthrough year for American CryoStem and its shareholders as we exit full time R&D and enter into global commercialization of our platform, “concluded Mr. Arnone.
Todd Markey, Vice President of Investor Relations Partners, said, “We are looking forward to delivering the American CryoStem investment story to beyond its existing shareholder base and the stem cell-based sector. We believe American CryoStem holds high interest to both value and biotech investors given our belief that the company is significantly undervalued when recognizing the company as a pioneer in the development of patented stem cell clinical processing and storage platforms. The company’s entry into global commercialization should help American CryoStem begin to generate an initial and growing revenue channel and set the company’s path towards profitability,” concluded Mr. Markey.
To be added to American CryoStem’s investor lists, please contact Todd Markey at Investor Relations Partners at 818-280-6800 or via email at tmarkey@irpartnersinc.com
About American CryoStem Corporation
Founded in 2008, American CryoStem (Ticker: CRYO) is a biotechnology pioneer, standardizing adipose tissue derived technologies for the fields of Regenerative and Personalized Medicine. The Company has developed Standard Operating Procedures (SOPs) to operate a state-of-art, FDA-registered, clinical laboratory dedicated to the collection, processing, bio-banking, culturing and differentiation of autologous adipose tissue (fat) and adipose derived stem cells (ADSCs). Leveraging platform technologies with 5+ developed products the Company is creating a global footprint of licensed laboratory affiliates and physicians networks to deliver current and future cellular applications.
The Company maintains a strategic portfolio of intellectual property that forms its standardized platform which supports a growing pipeline of stem cell applications and biologic products. The Company’s R&D efforts are focused on university and private collaborations to discover, develop and commercialize ADSC products by combining its platform with synergistic technologies to create jointly developed applications and intellectual property.
For additional information please visit: www.americancryostem.com www.personalcellsciences.comwww.acslaboratories.com
About Investor Relations Partners, Inc.
Investor Relations Partners, Inc. (IRP) www.irpartnersinc.com is a full-service investor relations firm serving clients from Los Angeles to New York to China. The principals of IRP have received top industry awards for their investor relations programs for a number of high-profile companies, including, but not limited to, Starwood Hotels & Resorts Worldwide (NYSE: HOT), ValueVision Media (Nasdaq: VVTV), Taro Pharmaceuticals (Nasdaq: TARO), and LJ International (Nasdaq: JADE). The firm’s principals have executed effective investor relations programs for dozens of public companies, ranging from emerging micro-cap companies to multinational corporations with market capitalizations in excess of $15 billion. For further information on IRP, please visit the firm’s Website at www.irpartnersinc.com.
Forward-Looking Statements
This press release may contain forward-looking statements, including information about management’s view of American CryoStem Corporation’s (“the Company”) future expectations, plans and prospects. In particular, when used in the preceding discussion, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this press release other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by American CryoStem Corporation.
